Alongside the first phase II clinical trial results of CDK4i/6i treatment in patients with advanced ALM, it was proposed following an analysis of 4 ALM patients that experienced clinical benefit and 5 ALM patients that did not experience clinical benefit to CDK4i/6i that low MCM7 expression and SH2B3 amplification could serve as predictive biomarkers of poor response to CDK4i/6i [8]. The gene discussed is SH2B3; the disease is acral lentiginous melanoma.